Volume 11, Issue 4 (10-2023)                   J. Pediatr. Rev 2023, 11(4): 289-292 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghaffari J. Antihistamines in Pregnancy. J. Pediatr. Rev 2023; 11 (4) :289-292
URL: http://jpr.mazums.ac.ir/article-1-559-en.html
Department of Allergy and Clinical Immunology, Molecular and Cellular Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. , javadneg@yahoo.com
Abstract:   (852 Views)
Allergic disorders are increasing prevalence from decades. Often of allergic diseases such as chronic urticaria in some aspects of quality of life of patients affected. Outdoor and indoor allergens can cause   aggravation of symptoms in allergic patients.
H1-antihistamines have been available for decades and those are over-the-counter drugs. The first generation H1-antihistamines have anticholinergic and sedative effects. Basically, their use (H1 blockers) for the routine management of allergic diseases is not recommended.  Second generation H1-antihistamines (bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, and rupatadine) have minimally or non-sedating and free of anticholinergic effects. About 10–15% of pregnant women used antihistamine within pregnancy.
Full-Text [PDF 271 kb]   (288 Downloads) |   |   Full-Text (HTML)  (165 Views)  
Type of Study: Letter to the Editor | Subject: Allergy and Clinical Immunology
Received: 2023/08/22 | Accepted: 2023/01/23 | Published: 2023/01/23

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Pediatrics Review

Designed & Developed by : Yektaweb